Ran GTPase (Ran) was used as control. == Conversation == PDX1 has been well established as a key factor in pancreas development and function (14,15), with homozygous mutations resulting in pancreas agenesis associated with neonatal diabetes, intrauterine growth retardation, and exocrine pancreas deficiency in humans and mice (10,11,16,17). two patients, which segregated with diabetes in the homozygous state. The mutation resulted in an E178G substitution in the PDX1 homeodomain. In contrast to other reportedPDX1mutations leading to neonatal diabetes and pancreas agenesis, homozygosity for the E178G mutation was not associated with clinical indicators of exocrine pancreas insufficiency. Further, the four heterozygous parents were not diabetic and displayed FGFR4-IN-1 normal glucose tolerance. Biochemical studies, however, revealed subclinical exocrine pancreas insufficiency in the patients and slightly reduced insulin secretion in the heterozygous parents. The E178G mutation resulted in reduced Pdx1 transactivation despite normal nuclear localization, expression level, and chromatin occupancy. == CONCLUSIONS == This study broadens the clinical spectrum ofPDX1mutations and justifies screening of this gene in neonatal diabetic patients even in the absence of exocrine pancreas manifestations. Although most cases of juvenile-onset insulin-dependent diabetes are represented by type 1 diabetes, in a subset of patients diabetes occurs in the neonatal period or very early. A number of monogenic defects have already been recognized to underlie these rare cases, and several genes have been recognized. Neonatal diabetes is usually permanent in approximately half of the patients and may be caused by mutations affecting genes that play a critical role in -cell development, survival, or function. Currently, monogenic causes are recognized in >50% cases of permanent insulin-dependent diabetes occurring before the age of 6 months (1). Genes responsible for monogenic neonatal FGFR4-IN-1 diabetes have been recognized by candidate gene studies (PDX1,GCK,HNF1B,KCNJ11, andABCC8), by linkage and positional gene identification in neonatal diabetes syndromes (EIF2AK3,FOXP3,PTF1A, andGLIS3), or by linkage and candidate gene study in nonsyndromic neonatal diabetes (INS) (rev. in1,2). While monogenic inheritance is usually very easily suspected in neonatal diabetes occurring FGFR4-IN-1 in association with other remarkable clinical features (syndromic diabetes), obtaining new genes responsible for nonsyndromic monogenic diabetes may be particularly challenging because these patients may be misclassified as type 1 diabetic. The observation that HLA class II alleles in patients with permanent insulin-dependent diabetes presenting before age 6 months was observed to be comparable to that of healthy controls (3,4) strongly supports the hypothesis that most cases of neonatal or very earlyonset diabetes have a different disease etiology than type 1 diabetes. Genetic study of highly selected families with monogenic inheritance is usually a powerful alternative to FGFR4-IN-1 identify these genes. Here, we studied a single extended family with two related patients affected by neonatal diabetes with Rabbit polyclonal to XPO7.Exportin 7 is also known as RanBP16 (ran-binding protein 16) or XPO7 and is a 1,087 aminoacid protein. Exportin 7 is primarily expressed in testis, thyroid and bone marrow, but is alsoexpressed in lung, liver and small intestine. Exportin 7 translocates proteins and large RNAsthrough the nuclear pore complex (NPC) and is localized to the cytoplasm and nucleus. Exportin 7has two types of receptors, designated importins and exportins, both of which recognize proteinsthat contain nuclear localization signals (NLSs) and are targeted for transport either in or out of thenucleus via the NPC. Additionally, the nucleocytoplasmic RanGTP gradient regulates Exportin 7distribution, and enables Exportin 7 to bind and release proteins and large RNAs before and aftertheir transportation. Exportin 7 is thought to play a role in erythroid differentiation and may alsointeract with cancer-associated proteins, suggesting a role for Exportin 7 in tumorigenesis no other clinical features. We showed that a novel homozygous mutation in thePDX1gene is responsible for diabetes in these patients, and we performed detailed clinical and functional investigations to determine the mechanisms responsible for this unexpected clinical presentation forPDX1mutation. == RESEARCH DESIGN AND METHODS == The family was of Moroccan Caucasian origin and was recognized through a diabetic child with neonatal insulin-dependent diabetes (subject 8), whose parents were consanguineous. A first cousin of the proband (subject 4) had comparable presenting manifestations and consanguineous parents. In the beginning, eight individuals (subjects 18) including the two patients, their parents, and unaffected siblings were FGFR4-IN-1 studied. Another child (subject 9) was born after the initial genetic study and was genetically diagnosed prenatally, and clinically confirmed subsequently, as nonaffected. The study was explained to the parents, who agreed to participate in the genetic study and in subsequent clinical and metabolic explorations and signed knowledgeable consents. The study protocol was approved by the Hospices Civils de Lyon. Blood samples were obtained on all family members, and DNA was extracted using standard procedures (observe Supplementary Methods, available in the online appendix athttp://diabetes.diabetesjournals.org/cgi/content/full/db09-1284/DC1). == Metabolic investigations. == Oral glucose tolerance test (OGTT) and intravenous glucose tolerance test (IVGTT) procedures were performed around the four parents (subjects 1, 2, 5, and 6) using.